IDOX has provided a trading update for the year ended 31 October 2024. Management expects to report full-year results in line with market expectations. Idox has delivered strong (c.20%) revenue growth and good adjusted EBITDA growth in the year, alongside healthy cash generation. Order growth of 9% is encouraging as it demonstrates both the underlying quality and strength, and the positive outlook. We look forward to the FY24 results to see how FY25 has started and how the growth story will continue.
Idox: Progressive
Nov 26, 2024Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.